Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Lymphoma 44Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Non-Hodgkin 22Multiple Myeloma 19Leukemia 17Burkitt Lymphoma 13Hodgkin Disease 12Lymphoma, Mantle-Cell 10Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Neoplasms, Plasma Cell 6Neoplasm Metastasis 6Lymphoma, T-Cell, Peripheral 6Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pain 3Lymphoma, B-Cell 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Leukemia, Biphenotypic, Acute 2Disease 2

Interventions

masitinib 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Castrate Resistant Prostate Cancer × Prednisone × Clear all
NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science

Phase 3 Completed
714 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡